All Updates

All Updates

icon
Filter
M&A
HOPE Therapeutics to acquire psychiatry clinics for USD 30 million
Psychedelic Medicine
Aug 26, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Aug 26, 2024

HOPE Therapeutics to acquire psychiatry clinics for USD 30 million

M&A

  • HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed non-binding term sheets for USD 30 million in non-dilutive financing to acquire interventional psychiatry clinics, including five operational clinics in the Western US.

  • With this acquisition, HOPE Therapeutics aims to create a unified network of clinics providing ketamine therapy and other treatments for suicidal depression, treatment-resistant depression, and post-traumatic stress disorder. The company plans to combine pharmaceutical therapy, FDA-approved medical technologies, digital therapeutics, and access to clinical trials for new treatments.

  • HOPE Therapeutics is developing a network of clinics focused on ketamine and other therapies for neurological and psychiatric disorders. The company aims to submit its new drug application to the FDA for its ketamine therapy to treat suicidal depression in 2H 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.